Please assess the completion status of the following clinical trial:

Trial Title: Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 12-18 years of age;~* able to swallow whole capsules;~* weighing ≥40kg;~* AST, ALT no more than 3 times the upper limit of normal for age and bilirubin concentrations within normal limits;~* receiving 2 consecutive (within 8 weeks) eligible, though not necessarily identical, IV chemotherapy cycles;~* English speaking (nausea assessment tool (PeNAT30) has been validated only in English)~* cognitive ability of the child believed to be at least at a 4 year old level according to parent or health care professional (to permit self-assessment of nausea severity).~Exclusion Criteria:~* receiving very cisplatin containing chemotherapy (aprepitant capsule administration to these patients is the current standard of care at Sick Kids)~* receiving chemotherapy within 5 days before,during or 5 days after either study cycle that is known or suspected to interact with aprepitant; that is, cyclophosphamide, doxorubicin, daunomycin, etoposide, irinotecan, ifosfamide, imatinib, paclitaxel, topotecan, vinorelbine, vinblastine and vincristine;~* receiving medication known to interact with aprepitant other than dexamethasone (see Appendix I for list of applicable agents and timeframe for exclusion);~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): This group will receive oral aprepitant on the first day of the first study cycle of chemotherapy. They will then cross-over to receive the capsule on the first day of the second study cycle of chemotherapy.
- Group 2 (Type: EXPERIMENTAL): This group will receive an aprepitant capsule on the first day of the first study cycle of chemotherapy. They will then cross-over to receive the oral aprepitant on the first day of the second study cycle of chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).